New first-line strategies are needed for metastatic #ColorectalCancer. The APICAL-CRC phase II trial finds promising #antitumor activity and manageable safety with sintilimab plus anlotinib in treatment-naïve patients.

#STTT #OpenAccess: doi.org/10.1038/s413...
#MetastaticCRC #Immunotherapy